BJH: Early use of corticosteroids for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy , approved for the treatment of relapsed/refractory large B-cell lymphoma (R /R LBCL)
.

In order to reduce the toxicity associated with axi-cel, several exploratory safety management cohorts have been added to ZUMA-1 (NCT02348216) , which is a key phase 1/2 study of axi-cel in refractory LBCL

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy , approved for the treatment of relapsed/refractory large B-cell lymphoma (R /R LBCL)

The patient received 2 × 10 ⁶ anti-CD19 CAR T cells/kg after pretreatment chemotherapy

Figure 1: ZUMA-1 queue 1 + 2 and queue 4 of the AE management specified by the agreement

Figure 2: ORR and response duration

Figure 2: ORR and response duration Figure 2: ORR and response duration

Figure 3: CAR T cell expansion and key soluble serum biomarker levels over time

Figure 3: CAR T cell expansion and key soluble serum biomarker levels over time Figure 3: CAR T cell expansion and key soluble serum biomarker levels over time

In conclusion, by down-regulating key pro-inflammatory soluble serum biomarkers (including cytokines), earlier and targeted use of corticosteroids and/or tocilizumab may reduce the incidence of grade 3 CRS and NE without It will significantly affect the expansion of CAR T cells and the remission rate of R/R LBCL patients who continue to receive axi-cel treatment
.

This method provides important additional information to further inform patient care

In conclusion, by down-regulating key pro-inflammatory soluble serum biomarkers (including cytokines), earlier and targeted use of corticosteroids and/or tocilizumab may reduce the incidence of grade 3 CRS and NE without It will significantly affect the expansion of CAR T cells and the remission rate of R/R LBCL patients who continue to receive axi-cel treatment

Original source:

Original source:

Topp, MS, van Meerten, T.

Topp, MS, van Meerten, T.
, Houot, R.
, Minnema, MC, Bouabdallah, K.
, Lugtenburg, PJ, Thieblemont, C.
, Wermke, M.
, Song, KW, Avivi, I.
, Kuruvilla, J .
, Dührsen, U.
, Zheng, Y.
, Vardhanabhuti, S.
, Dong, J.
, Bot, A.
, Rossi, JM, Plaks, V.
, Sherman, M.
, Kim, JJ, Kerber, A.
and Kersten, MJ (2021), Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol.
  https://doi.
org/10.
1111/bjh.
17673 Leave a message here